Olema Pharma Q3 net loss $22.7M; cash $222.6M; OP-1250 shows 41% tumor reduction

Olema Pharmaceuticals, Inc.

2022-Q3 EPS reported -$1.97

Net loss $22.7M in Q3 2022 vs $17.7M in Q3 2021; R&D expenses $17.6M GAAP ($14.8M non-GAAP).
Cash, equivalents and marketable securities $222.6M at Sept 30, 2022; sufficient into H2 2024.
OP-1250 monotherapy: 41% of heavily pre-treated patients had tumor reduction; 6 partial responses; Phase 2 fully enrolled.
OP-1250 + palbociclib combo: dose escalation completed, Phase 2 expansion ongoing; no dose-limiting toxicities.
Phase 3 monotherapy study planned for mid-2023; FDA Fast Track granted for ER+/HER2- metastatic breast cancer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Olema Pharmaceuticals, Inc. reported the quarter ended September 30, 2022 results: net income $22.7 million.

Period: the quarter ended September 30, 2022
Net income: $22.7 million
Result: reported results

Exact text from the filing

Net loss for the quarter ended September 30, 2022, was $22.7 million

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Olema Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-016899

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.